LMR Partners’s Oramed Pharmaceuticals ORMP Stock Holding History

LMR Partners’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,872	Closed	-$215K	–	1137
2022 Q4	$215K	Buy	17,872 +4,565	+34%	+$35.5K	﹤0.01%	988
2022 Q3	$86K	Hold	13,307	–	–	﹤0.01%	1064
2022 Q2	$61K	Buy	+13,307	New	+$71.1K	﹤0.01%	1143
2021 Q1	–	Sell	-23,093	Closed	-$98K	–	1036
2020 Q4	$98K	Sell	23,093 -9,897	-30%	-$32.2K	﹤0.01%	452
2020 Q3	$86K	Hold	32,990	–	–	﹤0.01%	372
2020 Q2	$116K	Buy	+32,990	New	+$111K	﹤0.01%	507

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's ORMP Position: Q1 2023 in Review

LMR Partners sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 17,872 shares — an estimated $215K sold.

LMR Partners first reported a position in ORMP in Q2 2020 and held it in 6 quarters. The position peaked at $215K in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

LMR Partners reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
LMR Partners sold 17,872 Oramed Pharmaceuticals shares in Q1 2023, an estimated $215K.
LMR Partners first reported a position in Oramed Pharmaceuticals in Q2 2020 and held it in 6 quarters.
LMR Partners's Oramed Pharmaceuticals position peaked at $215K in Q4 2022.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on LMR Partners's 13F filing for Q1 2023, filed 15 May 2023.